Back to Search Start Over

BCL6B Contributes to Ocular Vascular Diseases via Notch Signal Silencing.

Authors :
Tanaka M
Nakamura S
Sakaue T
Yamamoto T
Maekawa M
Nishinaka A
Yasuda H
Yunoki K
Sato Y
Sawa M
Yoshino K
Shimazawa M
Hatano M
Tokuhisa T
Higashiyama S
Hara H
Source :
Arteriosclerosis, thrombosis, and vascular biology [Arterioscler Thromb Vasc Biol] 2023 Jun; Vol. 43 (6), pp. 927-942. Date of Electronic Publication: 2023 Apr 20.
Publication Year :
2023

Abstract

Background: Endothelial cell activation is tightly controlled by the balance between VEGF (vascular endothelial cell growth factor) and Notch signaling pathway. VEGF destabilizes blood vessels and promotes neovascularization, which are common features of sight-threatening ocular vascular disorders. Here, we show that BCL6B (B-cell CLL/lymphoma 6 member B protein), also known as BAZF, ZBTB28, and ZNF62, plays a pivotal role in the development of retinal edema and neovascularization.<br />Methods: The pathophysiological physiological role of BCL6B was investigated in cellular and animal models mimicking 2 pathological conditions: retinal vein occlusion and choroidal neovascularization. An in vitro experimental system was used in which human retinal microvascular endothelial cells were supplemented with VEGF. Choroidal neovascularization cynomolgus monkey model was generated to investigate the involvement of BCL6B in the pathogenesis. Mice lacking BCL6B or treated with BCL6B-targeting small-interfering ribose nucleic acid were examined for histological and molecular phenotypes.<br />Results: In retinal endothelial cells, the BCL6B expression level was increased by VEGF. BCL6B-deficient endothelial cells showed Notch signal activation and attenuated cord formation via blockage of the VEGF-VEGFR2 signaling pathway. Optical coherence tomography images showed that choroidal neovascularization lesions were decreased by BCL6B-targeting small-interfering ribose nucleic acid. Although BCL6B mRNA expression was significantly increased in the retina, BCL6B-targeting small-interfering ribose nucleic acid suppressed ocular edema in the neuroretina. The increase in proangiogenic cytokines and breakdown of the inner blood-retinal barrier were abrogated in BCL6B knockout (KO) mice via Notch transcriptional activation by CBF1 (C promotor-binding factor 1) and its activator, the NICD (notch intracellular domain). Immunostaining showed that Müller cell activation, a source of VEGF, was diminished in BCL6B-KO retinas.<br />Conclusions: These data indicate that BCL6B may be a novel therapeutic target for ocular vascular diseases characterized by ocular neovascularization and edema.<br />Competing Interests: Disclosures H. Hara received a research grant from the Carna Biosciences Inc. K. Yunoki and Y. Sato were employees of Carna Biosciences Inc. M. Sawa and K. Yoshino were Chief Scientific Officer and Chief Executive Officer for the Carna Biosciences Inc, respectively, and they were stockholders in Carna Biosciences Inc at the time this study was conducted.

Details

Language :
English
ISSN :
1524-4636
Volume :
43
Issue :
6
Database :
MEDLINE
Journal :
Arteriosclerosis, thrombosis, and vascular biology
Publication Type :
Academic Journal
Accession number :
37078291
Full Text :
https://doi.org/10.1161/ATVBAHA.123.318987